Osteonecrosis treatment depends heavily on how far the disease has progressed and where it occurs in the body. In early stages, before the bone surface collapses, medications and joint-preserving surgeries can slow or halt the damage. Once the bone has collapsed significantly, joint replacement becomes the most reliable option. The hip is the most commonly affected site, but osteonecrosis also occurs in the knee, shoulder, and jaw, each requiring a somewhat different approach.
Why Staging Matters for Treatment
Osteonecrosis progresses through distinct stages, from invisible-on-X-ray to full joint destruction. The stage at diagnosis is the single biggest factor in determining which treatments are available to you. In the earliest stages (often called stage I or II), the bone is dying internally but the joint surface remains intact. This is the window where joint-preserving treatments work best. Once the bone surface collapses (stage III and beyond), the options narrow considerably.
MRI is the gold standard for catching osteonecrosis early because it can detect bone marrow changes long before they show up on standard X-rays. The size of the dead bone area also matters. Lesions smaller than about 15% of the femoral head respond much better to conservative surgery than larger ones. Lesions larger than 30% of the femoral head have a significantly greater chance of treatment failure.
Medications That Slow Bone Collapse
Bisphosphonates, drugs that slow the breakdown of bone tissue, are the most studied medications for osteonecrosis. A large study tracking over 870 hips found that oral bisphosphonate therapy allowed 74.5% of patients to avoid surgery over an average follow-up of nearly 11 years. A combination approach using both oral and intravenous bisphosphonates pushed that number to 88.9%, though with shorter follow-up.
The results varied significantly by stage. At three years, only about 4 to 5% of stage I patients experienced clinical failure, compared to roughly 10% of stage II patients and around 30% of stage III patients. Even when bisphosphonates didn’t prevent all radiographic changes, they consistently reduced the rate of bone collapse and delayed the need for joint replacement. Patients in these studies also took daily calcium and vitamin D supplements alongside their bisphosphonate therapy.
Core Decompression Surgery
Core decompression is the most widely used surgical procedure for early-stage osteonecrosis of the hip. A surgeon drills one or more small channels into the femoral head to relieve the pressure building up inside the dying bone. This reduces pain relatively quickly and creates pathways for new blood vessels to grow into the affected area.
The procedure works best for precollapse disease. In one long-term study, patients with stage I disease had a 96% hip survival rate at 10 years. That dropped to 74% for stage II and just 35% for stage III. Across a large review of surgeries performed after 1992, about 30% of hips eventually needed further surgery after an average follow-up of five years. A separate review found that roughly 26% of cases converted to total hip replacement within two years.
The ideal candidate has early-stage disease with a small area of dead bone. When the lesion is large or the bone surface has already started to collapse, core decompression alone is less likely to succeed. In those cases, surgeons often combine the procedure with bone grafting or other techniques to provide structural support.
Recovery After Core Decompression
After surgery, you’ll typically use crutches and limit how much weight you put on the affected leg. The goal is to protect the weakened bone while it heals and new blood supply develops. Physical therapy begins relatively soon, focusing first on gentle range-of-motion exercises and gradually progressing to strengthening. Full weight bearing usually resumes over a period of weeks, depending on the size of the lesion and your surgeon’s assessment of healing.
Bone Grafting Options
Bone grafting adds structural reinforcement to the weakened femoral head, often in combination with core decompression. There are two main types: grafts with their own blood supply (vascularized) and grafts without one (non-vascularized). The difference in outcomes is substantial.
In a study comparing the two approaches, vascularized fibular grafts had a collapse rate of just 14%, while non-vascularized grafts collapsed 70% of the time. Functional outcomes told a similar story: 70% of patients with vascularized grafts showed improved hip function scores, compared to 36% with non-vascularized grafts. Another study found less bone depression and lower rates of radiographic progression with vascularized grafts. The trade-off is that vascularized grafting is a more complex surgery requiring microsurgical expertise, so it’s performed at fewer centers.
Electromagnetic Bone Stimulation
Pulsed electromagnetic field (PEMF) therapy uses low-level electromagnetic energy to stimulate bone repair and protect cartilage. It’s typically used as an add-on treatment rather than a standalone approach. In a study of patients who received PEMF therapy (eight hours daily for six months) alongside core decompression and bone grafting, 81% of those with stage II disease had good clinical and radiographic outcomes with no pain or limping.
Success rates dropped at more advanced stages: 70% for stage III and just 27% radiographic improvement for stage IV. The therapy appears to work in two ways. In the short term, it protects joint cartilage from the inflammatory damage caused by bone marrow swelling. Over the longer term, it promotes new bone formation in the dead area and helps prevent the tiny fractures that lead to surface collapse.
Hyperbaric Oxygen Therapy
Hyperbaric oxygen therapy (HBOT) places you in a pressurized chamber breathing pure oxygen, which increases oxygen delivery to damaged bone tissue. It can reduce bone marrow swelling and improve local blood flow. Individual case reports have shown impressive pain reduction. In one case, a patient’s pain score dropped from 7 out of 10 to 2 after 20 sessions, and symptoms nearly disappeared after 50 sessions.
However, when pooled across multiple studies, the evidence is less convincing. A systematic review and meta-analysis found that while pain scores improved after HBOT, there was no significant difference in physical or mental health scores between patients who received hyperbaric oxygen and those who didn’t. The review concluded that HBOT cannot currently be considered an effective standalone treatment for early-stage femoral head osteonecrosis, though it may still play a role as a complementary therapy.
Stem Cell Therapy
Stem cell treatment for osteonecrosis involves harvesting cells from your own bone marrow, growing them in a lab over several weeks, then injecting them directly into the necrotic area using a needle guided by imaging. The goal is to introduce cells capable of forming new bone tissue in the damaged zone.
A clinical trial of eight patients with early-stage disease found that 75% experienced clinical improvement within the first year. No adverse effects from the cell injection were reported, and none of the patients needed hip replacement during that first year. Radiographic stabilization, meaning the disease stopped progressing on imaging, occurred in about 87.5% of patients in the short term.
The long-term picture was more sobering. After eight years, half of the treated patients eventually needed hip replacement surgery. The median time to replacement for those who needed it was about 19 months. Stem cell therapy remains an area of active investigation, and it’s not yet a standard treatment option at most centers.
Joint Replacement for Advanced Disease
When the bone surface has collapsed and the joint is damaged beyond repair, total hip replacement is the definitive treatment. It reliably eliminates pain and restores function, but osteonecrosis patients face some specific challenges compared to people getting hip replacements for arthritis.
In a long-term study comparing the two groups, 48% of osteonecrosis patients had unsatisfactory results after an average of seven years, compared to 33% of arthritis patients. The loosening of the implant’s femoral component was a particular problem: 28% in the osteonecrosis group versus just 5% in the arthritis group. The likely explanation is that extensive dead bone in the femoral head provides a weaker foundation for the implant. Patients with bilateral disease (both hips affected) and those with more advanced necrosis at the time of surgery were at highest risk for implant failure. Modern implant designs and surgical techniques have improved these numbers, but osteonecrosis patients should be aware that their implants may not last as long as average.
Jaw Osteonecrosis Treatment
Osteonecrosis of the jaw (often called MRONJ) is a distinct condition, usually triggered by medications like bisphosphonates or certain cancer drugs. Treatment follows a different path than hip osteonecrosis, starting with conservative measures in nearly all cases.
Initial management includes antibacterial mouth rinses, effective daily oral hygiene, and removal of any loose or superficial dead bone fragments that irritate the surrounding soft tissue. Routine antibiotics are not recommended unless there are clear signs of infection. For more advanced jaw osteonecrosis with exposed bone and infection, treatment escalates to include systemic antibiotics and more focused pain management. The emphasis throughout is on controlling infection, minimizing symptoms, and allowing the soft tissue to heal over the affected bone. Aggressive surgery is generally avoided because it can worsen the condition.